Jade Biosciences Announces Private Placement Agreement

An update from Jade Biosciences ( (JBIO) ) is now available.

On December 13, 2025, Jade Biosciences entered into a securities purchase agreement with BB Biotech for a private placement of 3,214,286 shares of common stock at $14.00 per share, expected to raise approximately $45 million. The proceeds will fund research and development, corporate expenses, and working capital. The private placement, exempt from public offering registration, is set to close on December 16, 2025, with a registration rights agreement to file a resale registration statement with the SEC.

The most recent analyst rating on (JBIO) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Jade Biosciences stock, see the JBIO Stock Forecast page.

Spark’s Take on JBIO Stock

According to Spark, TipRanks’ AI Analyst, JBIO is a Underperform.

Aerovate Therapeutics’ stock score reflects substantial financial challenges, including zero revenue and growing losses, which heavily weigh on the overall score. While there is positive momentum in technical analysis and significant corporate events such as the merger with Jade Biosciences, the negative valuation and financial instability are major concerns. The stock remains highly speculative with risks due to its financial performance.

To see Spark’s full report on JBIO stock, click here.

More about Jade Biosciences

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL and is under Phase 1 clinical trial for immunoglobulin A nephropathy, with other pipeline projects in preclinical development.

Average Trading Volume: 204,159

Technical Sentiment Signal: Buy

Current Market Cap: $689.1M

For an in-depth examination of JBIO stock, go to TipRanks’ Overview page.